WBB Securities is pleased to share a featured interview with our president, Dr. Steve Brozak, published in The Wall Street Transcript on April 29, 2025.
In this insightful article, Dr. Brozak explores the challenges and imperatives of returning pharmaceutical manufacturing to the United States. He discusses:
- The national security risks of foreign drug supply dependence
- Weak points in the global pharmaceutical supply chain
- Regulatory and cost-related barriers to domestic manufacturing
- The long-term benefits of reinvesting in U.S. production infrastructure
Dr. Brozak emphasizes that while the task is complex, onshoring drug manufacturing is essential to ensuring the safety, stability, and accessibility of our nation’s medical supply.
📄 Click here to read the full article (PDF)
This article originally appeared in The Wall Street Transcript and is reprinted here with permission. All rights reserved.
